Skip to main content

Table 1 (abstract O1). Proportion of responders at Week 16 by cohort

From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one

Cohort

Canakinumab (150 mg q4w), n/m (%)

Placebo n/m (%)

p-value

crFMF

19/31 (61.3)

2/32 (6.3)

<0.001*

HIDS/MKD

13/37 (35.1)

2/35 (5.7)

0.0020*

TRAPS

10/22 (45.5)

2/24 (8.3)

0.0050*

  1. n number of patients who responded, m number of patients evaluated for response
  2. *Statistical significance (1-sided) at the 0.025 level based on Fisher exact test/logistic regression model
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096